Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture

Ross C. Donehower, Joseph C. Allegra, Marc E Lippman, Bruce A. Chabner

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The combined effects of methotrexate and 5-fluoropyrimidines on the growth of a human breast cancer cell line in serum-free hormone-supplemented medium, lacking nucleosides, have been studied. All combinations of methotrexate (10-50 nM) and 5-fluorodeoxyuridine (10-100 nM) resulted in at least additive inhibition of cell growth and when analyzed by 50% response isobologram demonstrated synergism. Combinations of methotrexate (10-50 nM) and 5-fluorouracil (0.04-0.4 μM) gave enhanced inhibition as compared to single agents, but 50% response isobologram revealed only additive effects. The combination was most effective when methotrexate was added to the cultures prior to the 5-fluoropyrimidines or when the drugs were added simultaneously. The addition of 5-fluoropyrimidine prior to methotrexate appears to decrease the effect of the antifol on purine synthesis and lessen the cytotoxicity of the combination in this cell line.

Original languageEnglish
Pages (from-to)655-661
Number of pages7
JournalEuropean Journal of Cancer (1965)
Volume16
Issue number5
DOIs
StatePublished - Jan 1 1980
Externally publishedYes

Fingerprint

Methotrexate
Breast Neoplasms
Serum
Floxuridine
Cell Line
Growth
Nucleosides
Fluorouracil
5-fluoropyrimidine
Hormones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture. / Donehower, Ross C.; Allegra, Joseph C.; Lippman, Marc E; Chabner, Bruce A.

In: European Journal of Cancer (1965), Vol. 16, No. 5, 01.01.1980, p. 655-661.

Research output: Contribution to journalArticle

Donehower, Ross C. ; Allegra, Joseph C. ; Lippman, Marc E ; Chabner, Bruce A. / Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture. In: European Journal of Cancer (1965). 1980 ; Vol. 16, No. 5. pp. 655-661.
@article{c8bf6cabf9e54620a6a48579b5796ea5,
title = "Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture",
abstract = "The combined effects of methotrexate and 5-fluoropyrimidines on the growth of a human breast cancer cell line in serum-free hormone-supplemented medium, lacking nucleosides, have been studied. All combinations of methotrexate (10-50 nM) and 5-fluorodeoxyuridine (10-100 nM) resulted in at least additive inhibition of cell growth and when analyzed by 50{\%} response isobologram demonstrated synergism. Combinations of methotrexate (10-50 nM) and 5-fluorouracil (0.04-0.4 μM) gave enhanced inhibition as compared to single agents, but 50{\%} response isobologram revealed only additive effects. The combination was most effective when methotrexate was added to the cultures prior to the 5-fluoropyrimidines or when the drugs were added simultaneously. The addition of 5-fluoropyrimidine prior to methotrexate appears to decrease the effect of the antifol on purine synthesis and lessen the cytotoxicity of the combination in this cell line.",
author = "Donehower, {Ross C.} and Allegra, {Joseph C.} and Lippman, {Marc E} and Chabner, {Bruce A.}",
year = "1980",
month = "1",
day = "1",
doi = "10.1016/0014-2964(80)90206-6",
language = "English",
volume = "16",
pages = "655--661",
journal = "European journal of cancer",
issn = "0014-2964",
publisher = "Pergamon Press Ltd.",
number = "5",

}

TY - JOUR

T1 - Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture

AU - Donehower, Ross C.

AU - Allegra, Joseph C.

AU - Lippman, Marc E

AU - Chabner, Bruce A.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - The combined effects of methotrexate and 5-fluoropyrimidines on the growth of a human breast cancer cell line in serum-free hormone-supplemented medium, lacking nucleosides, have been studied. All combinations of methotrexate (10-50 nM) and 5-fluorodeoxyuridine (10-100 nM) resulted in at least additive inhibition of cell growth and when analyzed by 50% response isobologram demonstrated synergism. Combinations of methotrexate (10-50 nM) and 5-fluorouracil (0.04-0.4 μM) gave enhanced inhibition as compared to single agents, but 50% response isobologram revealed only additive effects. The combination was most effective when methotrexate was added to the cultures prior to the 5-fluoropyrimidines or when the drugs were added simultaneously. The addition of 5-fluoropyrimidine prior to methotrexate appears to decrease the effect of the antifol on purine synthesis and lessen the cytotoxicity of the combination in this cell line.

AB - The combined effects of methotrexate and 5-fluoropyrimidines on the growth of a human breast cancer cell line in serum-free hormone-supplemented medium, lacking nucleosides, have been studied. All combinations of methotrexate (10-50 nM) and 5-fluorodeoxyuridine (10-100 nM) resulted in at least additive inhibition of cell growth and when analyzed by 50% response isobologram demonstrated synergism. Combinations of methotrexate (10-50 nM) and 5-fluorouracil (0.04-0.4 μM) gave enhanced inhibition as compared to single agents, but 50% response isobologram revealed only additive effects. The combination was most effective when methotrexate was added to the cultures prior to the 5-fluoropyrimidines or when the drugs were added simultaneously. The addition of 5-fluoropyrimidine prior to methotrexate appears to decrease the effect of the antifol on purine synthesis and lessen the cytotoxicity of the combination in this cell line.

UR - http://www.scopus.com/inward/record.url?scp=0018850717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018850717&partnerID=8YFLogxK

U2 - 10.1016/0014-2964(80)90206-6

DO - 10.1016/0014-2964(80)90206-6

M3 - Article

C2 - 6446455

AN - SCOPUS:0018850717

VL - 16

SP - 655

EP - 661

JO - European journal of cancer

JF - European journal of cancer

SN - 0014-2964

IS - 5

ER -